ALP
AlphaTON Capital Corp.
NASDAQ · Healthcare · Biotechnology · VG
$0.10
−13.74%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +93.3%
- EPS
- +96.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -24.4%
- EBIT
- —
- Net income
- —
- EPS
- +26.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026